Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine in Post-LASIK Patients
NCT00991458Phase 2Completed
- Sponsor
- Allergan
- Start
- Oct 2009
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cyclosporine 2% ophthalmic solution in Corneal hypoesthesia and dry eye disease (DED) (3 arms), sponsored by Allergan. Primary endpoint: Time to Cure (Recovery of Corneal Sensitivity) at 6 months. Started Oct 2009; status: completed.
02
Drugs
cyclosporine 2% ophthalmic solution
03
Conditions
Corneal hypoesthesiadry eye disease (DED)
Beyond the preview
Go deeper on NCT00991458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00991458.